首页 > 最新文献

Human Immunology最新文献

英文 中文
A wide proteome analysis to engineer an efficient epitope based vaccine against Salmonella Typhi: An immunoinformatic study 一个广泛的蛋白质组分析来设计一个有效的基于表位的伤寒沙门氏菌疫苗:一项免疫信息学研究。
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-04-01 Epub Date: 2026-02-11 DOI: 10.1016/j.humimm.2026.111684
Mahsa Beiranvand , Nemat Shams , Amin Jaydari , Narges Nazifi , Peyman Khademi

Background

Typhoid fever, a potentially fatal disease caused by Salmonella enterica serovar Typhi, requires effective vaccines. This study aimed to design a recombinant subunit vaccine using the most immunogenic proteins from the Salmonella Typhi proteome.

Methods

Initially, the most antigenic proteins were selected to predict linear T-cell, B-cell, and IFN-γ epitopes. A recombinant construct incorporating these epitopes, peptide linkers, and a molecular adjuvant was designed. Comprehensive evaluation assessed physicochemical properties, solubility, secondary/tertiary structure, antigenicity, and immune stimulation potential. Molecular docking and dynamics simulations investigated binding to the TLR4/MD2 receptor complex.

Results

Seven proteins from 4322 were chosen for epitope prediction, yielding a 655-amino acid construct. Physicochemical analysis showed 40.31 % hydrophobic amino acids, an aliphatic index of 53.66, GRAVY index of −0.712, and instability index of 22.34. Structural composition was 53.53 % alpha-helix, 8.85 % extended strand, and 40.61 % random coil. Immune simulations demonstrated significant enhancement of primary/secondary humoral and cellular immune responses. The vaccine construct effectively bound the TLR4/MD2 receptor via significant hydrogen bonding (affinity: −1019.1 kcal/mol). Molecular dynamics simulations confirmed the stability of this interaction over 200 ns, demonstrating that both the vaccine candidate and receptor remained structurally stable throughout the simulation period.

Conclusion

Typhoid vaccine candidate shows immunogenic properties, robust immune responses and stable TLR4/MD2 receptor binding.
背景:伤寒是一种由伤寒沙门氏菌引起的潜在致命疾病,需要有效的疫苗。本研究旨在利用伤寒沙门氏菌蛋白组中免疫原性最强的蛋白设计重组亚单位疫苗。方法:首先,选择最具抗原性的蛋白来预测线性t细胞、b细胞和IFN-γ表位。设计了包含这些表位、肽连接体和分子佐剂的重组结构。综合评价评估了理化性质、溶解度、二级/三级结构、抗原性和免疫刺激潜力。分子对接和动力学模拟研究了与TLR4/MD2受体复合物的结合。结果:从4322中选择7个蛋白进行表位预测,得到655个氨基酸的结构。理化分析表明,疏水氨基酸占总氨基酸的40.31%,脂肪族指数为53.66,肉汁指数为-0.712,不稳定性指数为22.34。结构组成为53.53%的螺旋体,8.85%的延伸链,40.61%的随机线圈。免疫模拟显示了原发性/继发性体液和细胞免疫反应的显著增强。该疫苗结构通过显著的氢键有效结合TLR4/MD2受体(亲和力:-1019.1 kcal/mol)。分子动力学模拟证实了这种相互作用在200 ns内的稳定性,表明候选疫苗和受体在整个模拟期间都保持结构稳定。结论:伤寒候选疫苗具有免疫原性,免疫应答强,TLR4/MD2受体结合稳定。
{"title":"A wide proteome analysis to engineer an efficient epitope based vaccine against Salmonella Typhi: An immunoinformatic study","authors":"Mahsa Beiranvand ,&nbsp;Nemat Shams ,&nbsp;Amin Jaydari ,&nbsp;Narges Nazifi ,&nbsp;Peyman Khademi","doi":"10.1016/j.humimm.2026.111684","DOIUrl":"10.1016/j.humimm.2026.111684","url":null,"abstract":"<div><h3>Background</h3><div>Typhoid fever, a potentially fatal disease caused by <em>Salmonella</em> enterica serovar Typhi, requires effective vaccines. This study aimed to design a recombinant subunit vaccine using the most immunogenic proteins from the <em>Salmonella</em> Typhi proteome.</div></div><div><h3>Methods</h3><div>Initially, the most antigenic proteins were selected to predict linear T-cell, B-cell, and IFN-γ epitopes. A recombinant construct incorporating these epitopes, peptide linkers, and a molecular adjuvant was designed. Comprehensive evaluation assessed physicochemical properties, solubility, secondary/tertiary structure, antigenicity, and immune stimulation potential. Molecular docking and dynamics simulations investigated binding to the TLR4/MD2 receptor complex.</div></div><div><h3>Results</h3><div>Seven proteins from 4322 were chosen for epitope prediction, yielding a 655-amino acid construct. Physicochemical analysis showed 40.31 % hydrophobic amino acids, an aliphatic index of 53.66, GRAVY index of −0.712, and instability index of 22.34. Structural composition was 53.53 % alpha-helix, 8.85 % extended strand, and 40.61 % random coil. Immune simulations demonstrated significant enhancement of primary/secondary humoral and cellular immune responses. The vaccine construct effectively bound the TLR4/MD2 receptor via significant hydrogen bonding (affinity: −1019.1 kcal/mol). Molecular dynamics simulations confirmed the stability of this interaction over 200 ns, demonstrating that both the vaccine candidate and receptor remained structurally stable throughout the simulation period.</div></div><div><h3>Conclusion</h3><div>Typhoid vaccine candidate shows immunogenic properties, robust immune responses and stable TLR4/MD2 receptor binding.</div></div>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 4","pages":"Article 111684"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146183455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of complement protein and complement regulatory protein in diabetic nephropathy 补体蛋白和补体调节蛋白在糖尿病肾病中的作用
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-04-01 Epub Date: 2026-02-12 DOI: 10.1016/j.humimm.2026.111686
Xiaoxiang Jiang , Zhanzhan Sun

Background

Diabetic nephropathy is one of the main causes of end-stage renal disease, with dysregulation of the complement system playing a critical role in its pathogenesis. However, the specific mechanisms, key effector molecules, and relevant therapeutic targets still require further investigation.

Methods

This review involves searching databases such as PubMed and Web of Science to identify and integrate key studies on the role of complement proteins and regulatory proteins in diabetic nephropathy. This is a narrative review integrating experimental and clinical studies, rather than a formal systematic review. The analysis systematically examines the mechanisms of the complement system in disease progression and its potential as a therapeutic target.

Results

This review collectively suggests that the hyperglycemic environment characteristic of diabetic nephropathy activates both the complement alternative and lectin pathways, continuously driving the complement cascade and generating key effector molecules (such as C5a and the membrane attack complex). These molecules directly lead to podocyte injury, glomerular inflammation, and fibrosis. Concurrently, dysfunction of complement regulatory proteins (such as CD59 and CD55) results in excessive activation of complement proteins, collectively accelerating the progression of diabetic nephropathy to end-stage renal disease. In terms of intervention strategies, inhibitors targeting specific complement components (such as C3 and C5) have shown protective effects in preclinical models.

Conclusion

Dysregulation of the complement system is an important pathogenic mechanism in diabetic nephropathy. A deeper understanding of this regulatory network provides a solid theoretical foundation for developing targeted and precise therapeutic strategies aimed at the complement system.
背景:糖尿病肾病是终末期肾脏疾病的主要病因之一,补体系统失调在其发病机制中起关键作用。但其具体机制、关键效应分子及相关治疗靶点仍有待进一步研究。方法检索PubMed和Web of Science等数据库,识别并整合补体蛋白和调节蛋白在糖尿病肾病中作用的关键研究。这是一篇综合实验和临床研究的叙述性综述,而不是一篇正式的系统综述。该分析系统地检查了补体系统在疾病进展中的机制及其作为治疗靶点的潜力。结果糖尿病肾病的高血糖环境特征激活了补体替代途径和凝集素途径,持续驱动补体级联并产生关键效应分子(如C5a和膜攻击复合物)。这些分子直接导致足细胞损伤、肾小球炎症和纤维化。同时,补体调节蛋白(如CD59和CD55)功能障碍导致补体蛋白过度活化,共同加速糖尿病肾病向终末期肾病的进展。在干预策略方面,针对特定补体成分(如C3和C5)的抑制剂在临床前模型中显示出保护作用。结论补体系统失调是糖尿病肾病的重要发病机制。对这一调控网络的深入了解为开发针对补体系统的靶向和精确治疗策略提供了坚实的理论基础。
{"title":"The role of complement protein and complement regulatory protein in diabetic nephropathy","authors":"Xiaoxiang Jiang ,&nbsp;Zhanzhan Sun","doi":"10.1016/j.humimm.2026.111686","DOIUrl":"10.1016/j.humimm.2026.111686","url":null,"abstract":"<div><h3>Background</h3><div>Diabetic nephropathy is one of the main causes of end-stage renal disease, with dysregulation of the complement system playing a critical role in its pathogenesis. However, the specific mechanisms, key effector molecules, and relevant therapeutic targets still require further investigation.</div></div><div><h3>Methods</h3><div>This review involves searching databases such as PubMed and Web of Science to identify and integrate key studies on the role of complement proteins and regulatory proteins in diabetic nephropathy. This is a narrative review integrating experimental and clinical studies, rather than a formal systematic review. The analysis systematically examines the mechanisms of the complement system in disease progression and its potential as a therapeutic target.</div></div><div><h3>Results</h3><div>This review collectively suggests that the hyperglycemic environment characteristic of diabetic nephropathy activates both the complement alternative and lectin pathways, continuously driving the complement cascade and generating key effector molecules (such as C5a and the membrane attack complex). These molecules directly lead to podocyte injury, glomerular inflammation, and fibrosis. Concurrently, dysfunction of complement regulatory proteins (such as CD59 and CD55) results in excessive activation of complement proteins, collectively accelerating the progression of diabetic nephropathy to end-stage renal disease. In terms of intervention strategies, inhibitors targeting specific complement components (such as C3 and C5) have shown protective effects in preclinical models.</div></div><div><h3>Conclusion</h3><div>Dysregulation of the complement system is an important pathogenic mechanism in diabetic nephropathy. A deeper understanding of this regulatory network provides a solid theoretical foundation for developing targeted and precise therapeutic strategies aimed at the complement system.</div></div>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 4","pages":"Article 111686"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146192375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and dynamics of HLA Donor-Specific antibodies in Simultaneous Liver-Kidney transplantation HLA供者特异性抗体在同步肝肾移植中的流行和动态
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-04-01 Epub Date: 2026-02-12 DOI: 10.1016/j.humimm.2026.111679
Qiuheng Zhang , Mario A. Pulido , Sofia Soltero , Carrie Butler , Erik Lum , Basmah Abdalla , Elizabeth Kendrick , Julie M. Yabu , Phuong-Thu Pham , Suphamai Bunnapradist , Jeffrey Veale , Albin H. Gritsch , Gabriel M. Danovitch , Robert S. Venick , Harry Pickering , Douglas G. Farmer , Elaine F. Reed

Aims

Donor-specific antibodies (DSAs) negatively affect outcomes in solid organ transplantation outcomes, but their significance in simultaneous liver-kidney (SLK) transplant recipients remains incompletely understood. This study investigates the prevalence, dynamics, and clinical impact of both preformed and posttransplant DSAs in patients undergoing SLK transplantation.

Methods

A retrospective cohort of 151 SLK recipients transplanted at UCLA from 2014 to 2024 was analyzed. Assessment of DSA status, DSA strength (mean fluorescence intensity (MFI), and clinical outcomes including rejection and patient survival were performed. Patient survival was analyzed using Kaplan–Meier survival curves.

Results

Of the 151 patients, 35 (23.2 %) were transplanted with preformed DSAs. Among 110 patients with posttransplant DSA testing, 25 (22.7 %) developed new DSAs, with a significantly higher incidence in females (37.8 % vs. 15.1 %, p = 0.014). Preformed DSAs were not significantly associated with rejection in kidney, liver, or combined allografts. However, posttransplant DSAs correlated with increased rejection risk: 3/25 (12 %) vs. 1/85 (1.2 %) in kidney (p < 0.05) alone and 12 % vs. 8.2 % in liver (p < 0.05) alone. Four patients experienced antibody-mediated rejection, and all four patients had either preformed or posttransplant de novo DSA. Preformed Class II DSAs were more persistent posttransplant and were more frequently associated with rejection (p < 0.05). Both preformed and posttransplant DSAs significantly declined over time posttransplant, although class II DSAs exhibited more resistance to clearance compared to class I DSA. Survival analysis revealed no statistically significant differences among patients without DSA, preformed DSA and posttransplant DSA groups; however, patients without DSAs had the highest 5-year survival (74.3 %), while those developing de novo DSAs beyond 3 months had the lowest (48.4 %).

Conclusions

In SLK recipients, posttransplant DSAs, especially class II, are significantly associated with increased rejection risk and may contribute to reduced long-term survival. Although preformed DSAs showed less clinical impact, persistent class II DSAs warrant closer monitoring. Larger studies are needed to validate these findings and guide individualized immunological risk assessment.
目的:供体特异性抗体(dsa)对实体器官移植结果有负面影响,但其在同时进行肝肾移植(SLK)受者中的意义仍不完全清楚。本研究调查了SLK移植患者术前和术后dsa的患病率、动态和临床影响。方法对2014年至2024年在加州大学洛杉矶分校移植的151例SLK受体进行回顾性队列分析。评估DSA状态、DSA强度(平均荧光强度(MFI))和临床结果,包括排斥反应和患者生存。采用Kaplan-Meier生存曲线分析患者生存。结果151例患者中,35例(23.2%)采用预成型dsa移植。在110例移植后DSA检测患者中,有25例(22.7%)出现新的DSA,其中女性的发生率明显更高(37.8% vs. 15.1%, p = 0.014)。预形成的dsa与肾、肝或联合同种异体移植的排斥反应无显著相关性。然而,移植后dsa与排斥风险增加相关:肾脏(p < 0.05)单独为3/25(12%)对1/85(1.2%),肝脏单独为12%对8.2% (p < 0.05)。4例患者出现了抗体介导的排斥反应,所有4例患者在移植前或移植后都发生了从头DSA。预形成的II类dsa在移植后更持久,更常与排斥反应相关(p < 0.05)。移植前和移植后的DSA均随移植后时间的推移而显著下降,尽管与I类DSA相比,II类DSA表现出更强的清除阻力。生存分析显示,无DSA组、术前DSA组和移植后DSA组间差异无统计学意义;然而,没有dsa的患者的5年生存率最高(74.3%),而新发dsa超过3个月的患者的5年生存率最低(48.4%)。结论在SLK受者中,移植后dsa,特别是II类,与排斥风险增加显著相关,并可能导致长期生存率降低。尽管预成形dsa的临床影响较小,但持续的II级dsa需要更密切的监测。需要更大规模的研究来验证这些发现并指导个体化免疫风险评估。
{"title":"Prevalence and dynamics of HLA Donor-Specific antibodies in Simultaneous Liver-Kidney transplantation","authors":"Qiuheng Zhang ,&nbsp;Mario A. Pulido ,&nbsp;Sofia Soltero ,&nbsp;Carrie Butler ,&nbsp;Erik Lum ,&nbsp;Basmah Abdalla ,&nbsp;Elizabeth Kendrick ,&nbsp;Julie M. Yabu ,&nbsp;Phuong-Thu Pham ,&nbsp;Suphamai Bunnapradist ,&nbsp;Jeffrey Veale ,&nbsp;Albin H. Gritsch ,&nbsp;Gabriel M. Danovitch ,&nbsp;Robert S. Venick ,&nbsp;Harry Pickering ,&nbsp;Douglas G. Farmer ,&nbsp;Elaine F. Reed","doi":"10.1016/j.humimm.2026.111679","DOIUrl":"10.1016/j.humimm.2026.111679","url":null,"abstract":"<div><h3>Aims</h3><div>Donor-specific antibodies (DSAs) negatively affect outcomes in solid organ transplantation outcomes, but their significance in simultaneous liver-kidney (SLK) transplant recipients remains incompletely understood. This study investigates the prevalence, dynamics, and clinical impact of both preformed and posttransplant DSAs in patients undergoing SLK transplantation.</div></div><div><h3>Methods</h3><div>A retrospective cohort of 151 SLK recipients transplanted at UCLA from 2014 to 2024 was analyzed. Assessment of DSA status, DSA strength (mean fluorescence intensity (MFI), and clinical outcomes including rejection and patient survival were performed. Patient survival was analyzed using Kaplan–Meier survival curves.</div></div><div><h3>Results</h3><div>Of the 151 patients, 35 (23.2 %) were transplanted with preformed DSAs. Among 110 patients with posttransplant DSA testing, 25 (22.7 %) developed new DSAs, with a significantly higher incidence in females (37.8 % vs. 15.1 %, <em>p</em> = 0.014). Preformed DSAs were not significantly associated with rejection in kidney, liver, or combined allografts. However, posttransplant DSAs correlated with increased rejection risk: 3/25 (12 %) vs. 1/85 (1.2 %) in kidney (<em>p</em> &lt; 0.05) alone and 12 % vs. 8.2 % in liver (<em>p</em> &lt; 0.05) alone. Four patients experienced antibody-mediated rejection, and all four patients had either preformed or posttransplant <em>de novo</em> DSA. Preformed Class II DSAs were more persistent posttransplant and were more frequently associated with rejection (p &lt; 0.05). Both preformed and posttransplant DSAs significantly declined over time posttransplant, although class II DSAs exhibited more resistance to clearance compared to class I DSA. Survival analysis revealed no statistically significant differences among patients without DSA, preformed DSA and posttransplant DSA groups; however, patients without DSAs had the highest 5-year survival (74.3 %), while those developing de novo DSAs beyond 3 months had the lowest (48.4 %).</div></div><div><h3>Conclusions</h3><div>In SLK recipients, posttransplant DSAs, especially class II, are significantly associated with increased rejection risk and may contribute to reduced long-term survival. Although preformed DSAs showed less clinical impact, persistent class II DSAs warrant closer monitoring. Larger studies are needed to validate these findings and guide individualized immunological risk assessment.</div></div>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 4","pages":"Article 111679"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146192438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical and Clinical Developments in Treg Therapy for Heart Transplantation: Critical Assessment and Translational Challenges 心脏移植Treg治疗的临床前和临床进展:关键评估和转化挑战。
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-04-01 Epub Date: 2026-02-10 DOI: 10.1016/j.humimm.2026.111681
Konstantinos Mengrelis , Laurenz Wolner , Rayna Lellis Lakatos , Andreas Zuckermann , Nina Pilat
Regulatory T cells (Tregs) represent a promising approach to induce donor-specific tolerance in cardiac transplantation, potentially reducing reliance on chronic immunosuppression. This review critically evaluates preclinical and clinical evidence. Preclinical studies demonstrate that adoptively transferred Tregs prolong cardiac allograft survival and prevent chronic allograft vasculopathy (CAV) in murine models through multiple suppressive mechanisms. Phase I/II trials in kidney and liver transplantation have already confirmed safety and feasibility of polyclonal Treg cell therapy, with evidence of immunosuppression reduction in selected patients. However, no cardiac-specific trials have been completed in adults, and critical translational barriers persist including limited in vivo persistence, phenotypic instability under inflammatory conditions, manufacturing complexity and incompatibility with deceased donor timelines. Emerging approaches show promise: CAR-engineered Tregs targeting HLA-A2 demonstrate enhanced specificity and establish infectious tolerance in preclinical cardiac transplant models, with preliminary data from the first-in-human kidney transplant data suggesting safety and efficacy. Thymus-derived Tregs offer advantages for pediatric recipients, with the first treated cardiac transplant patient showing preserved Treg homeostasis. This review identifies key research priorities necessary to translate Treg therapy into clinical cardiac transplantation practice.
调节性T细胞(Tregs)代表了在心脏移植中诱导供体特异性耐受性的一种有前景的方法,可能减少对慢性免疫抑制的依赖。本综述对临床前和临床证据进行了批判性评价。临床前研究表明,过继性转移Tregs通过多种抑制机制延长同种异体心脏移植存活并预防小鼠模型中的慢性同种异体血管病变(CAV)。肾和肝移植的I/II期试验已经证实了多克隆Treg细胞治疗的安全性和可行性,有证据表明,在选定的患者中免疫抑制减少。然而,目前尚未在成人中完成心脏特异性试验,关键的翻译障碍仍然存在,包括有限的体内持久性、炎症条件下的表型不稳定性、制造复杂性和与已故供者时间线的不兼容性。新兴方法显示出希望:car修饰的靶向HLA-A2的Tregs在临床前心脏移植模型中表现出增强的特异性,并建立了感染耐受性,首次人体肾移植数据的初步数据表明安全性和有效性。胸腺源性Treg为儿科受者提供了优势,第一例接受心脏移植治疗的患者显示Treg保持稳态。本综述确定了将Treg疗法转化为临床心脏移植实践所需的关键研究重点。
{"title":"Preclinical and Clinical Developments in Treg Therapy for Heart Transplantation: Critical Assessment and Translational Challenges","authors":"Konstantinos Mengrelis ,&nbsp;Laurenz Wolner ,&nbsp;Rayna Lellis Lakatos ,&nbsp;Andreas Zuckermann ,&nbsp;Nina Pilat","doi":"10.1016/j.humimm.2026.111681","DOIUrl":"10.1016/j.humimm.2026.111681","url":null,"abstract":"<div><div>Regulatory T cells (Tregs) represent a promising approach to induce donor-specific tolerance in cardiac transplantation, potentially reducing reliance on chronic immunosuppression. This review critically evaluates preclinical and clinical evidence. Preclinical studies demonstrate that adoptively transferred Tregs prolong cardiac allograft survival and prevent chronic allograft vasculopathy (CAV) in murine models through multiple suppressive mechanisms. Phase I/II trials in kidney and liver transplantation have already confirmed safety and feasibility of polyclonal Treg cell therapy, with evidence of immunosuppression reduction in selected patients. However, no cardiac-specific trials have been completed in adults, and critical translational barriers persist including limited in vivo persistence, phenotypic instability under inflammatory conditions, manufacturing complexity and incompatibility with deceased donor timelines. Emerging approaches show promise: CAR-engineered Tregs targeting HLA-A2 demonstrate enhanced specificity and establish infectious tolerance in preclinical cardiac transplant models, with preliminary data from the first-in-human kidney transplant data suggesting safety and efficacy. Thymus-derived Tregs offer advantages for pediatric recipients, with the first treated cardiac transplant patient showing preserved Treg homeostasis. This review identifies key research priorities necessary to translate Treg therapy into clinical cardiac transplantation practice.</div></div>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 4","pages":"Article 111681"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The limited clinical utility of Neutrophil-to-Lymphocyte ratio in systemic lupus Erythematosus: A Meta-Analysis with external validation 中性粒细胞与淋巴细胞比值在系统性红斑狼疮中的有限临床应用:一项具有外部验证的荟萃分析
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-04-01 Epub Date: 2026-02-05 DOI: 10.1016/j.humimm.2026.111683
Jingxue Du , Xiangping Tu , Manrong He , Yongdi Zuo, Lei Chen, Mengfei Li, Wanxin Tang

Objective

To evaluate the diagnostic and discriminative value of the neutrophil-to-lymphocyte ratio (NLR) in systemic lupus erythematosus (SLE).

Methods

A meta-analysis was conducted using literature from inception to January 2026. Pooled estimates were calculated, and external validation was provided by a single-center study (n = 290).

Results

Forty studies were included. NLR was significantly higher in SLE patients than healthy controls (SMD = 0.850). Patients with lupus nephritis (LN) and active disease also exhibited elevated NLR. A positive correlation was found between NLR and SLEDAI scores (pooled r = 0.330); however, this decreased to 0.200 after trim-and-fill adjustment for publication bias, a finding consistent with external validation (r = 0.210). Its discriminatory accuracy was generally limited (AUC 0.668–0.757), with ethnicity and treatments being major sources of heterogeneity.

Conclusion

NLR is elevated in SLE, LN, and active disease, showing a weak positive correlation with disease activity. However, its clinical utility is influenced by ethnicity and treatment, indicating that it should not be used as an independent biomarker but may have a role as part of a combined assessment.
目的探讨中性粒细胞与淋巴细胞比值(NLR)对系统性红斑狼疮(SLE)的诊断和鉴别价值。方法采用文献荟萃分析,时间自成立至2026年1月。计算汇总估计,并通过一项单中心研究(n = 290)进行外部验证。结果共纳入40项研究。SLE患者NLR明显高于健康对照组(SMD = 0.850)。狼疮性肾炎(LN)和活动性疾病患者也表现出NLR升高。NLR与SLEDAI评分呈正相关(合并r = 0.330);然而,在对发表偏倚进行调整后,这一数据降至0.200,这一发现与外部验证一致(r = 0.210)。其鉴别准确度一般有限(AUC 0.668-0.757),种族和治疗是异质性的主要来源。结论nlr在SLE、LN和活动性疾病中升高,与疾病活动性呈弱正相关。然而,其临床效用受到种族和治疗的影响,这表明它不应作为独立的生物标志物使用,而可以作为综合评估的一部分。
{"title":"The limited clinical utility of Neutrophil-to-Lymphocyte ratio in systemic lupus Erythematosus: A Meta-Analysis with external validation","authors":"Jingxue Du ,&nbsp;Xiangping Tu ,&nbsp;Manrong He ,&nbsp;Yongdi Zuo,&nbsp;Lei Chen,&nbsp;Mengfei Li,&nbsp;Wanxin Tang","doi":"10.1016/j.humimm.2026.111683","DOIUrl":"10.1016/j.humimm.2026.111683","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the diagnostic and discriminative value of the neutrophil-to-lymphocyte ratio (NLR) in systemic lupus erythematosus (SLE).</div></div><div><h3>Methods</h3><div>A <em>meta</em>-analysis was conducted using literature from inception to January 2026. Pooled estimates were calculated, and external validation was provided by a single-center study (n = 290).</div></div><div><h3>Results</h3><div>Forty studies were included. NLR was significantly higher in SLE patients than healthy controls (SMD = 0.850). Patients with lupus nephritis (LN) and active disease also exhibited elevated NLR. A positive correlation was found between NLR and SLEDAI scores (pooled r = 0.330); however, this decreased to 0.200 after trim-and-fill adjustment for publication bias, a finding consistent with external validation (r = 0.210). Its discriminatory accuracy was generally limited (AUC 0.668–0.757), with ethnicity and treatments being major sources of heterogeneity.</div></div><div><h3>Conclusion</h3><div>NLR is elevated in SLE, LN, and active disease, showing a weak positive correlation with disease activity. However, its clinical utility is influenced by ethnicity and treatment, indicating that it should not be used as an independent biomarker but may have a role as part of a combined assessment.</div></div>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 4","pages":"Article 111683"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146116507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unique case of False-Positive pan-HLA-A antibody detection in LABScreen single antigen bead assay 伪阳性泛hla - a抗体检测在LABScreen单抗原珠试验中的独特案例。
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-04-01 Epub Date: 2026-02-10 DOI: 10.1016/j.humimm.2026.111682
Merschman Jarret, Barnes Rachel, Burmeister Lydia, Kreuter Justin, Park Robyn, Theel Nathan, Wakefield Laurie, Manish J. Gandhi
Accurate detection of HLA antibodies is essential for assessing immunologic risk in transplantation. Solid-phase antibody assays (SPA), particularly Luminex-based single-antigen bead (SAB) assay offer high sensitivity, but are prone to false reactions that may lead to clinical misinterpretation. While false-positive pan-locus patterns have been described for HLA-C/DR, pan-HLA-A reactivity has not been previously reported.
We present a patient who developed pan-HLA-A reactivity detected by LABScreen™ SAB one year after combined liver-kidney transplantation. Repeat testing and Presorb™ treatment yielded identical results. To investigate causes, testing with acid-treated beads ruled out antibodies to denatured HLA. An alternative SAB platform (LIFECODES® LSA™) and LABScreen™ Mixed beads were negative. Surrogate flow crossmatches with two unrelated donors were negative, confirming absence of cell-reactive antibodies.
This represents the first documented case of false-positive pan–HLA-A reactivity confined to a single commercial SAB product. Recognition of such artifacts is essential to prevent misclassification of antibody specificity.
HLA抗体的准确检测是评估移植免疫风险的关键。固相抗体测定(SPA),特别是基于luminex的单抗原珠(SAB)测定具有高灵敏度,但容易产生可能导致临床误解的错误反应。虽然对HLA-C/DR的泛基因座模式有假阳性的描述,但泛hla - a反应性以前没有报道。我们报告了一名患者在肝肾联合移植一年后出现了LABScreen™SAB检测的泛hla - a反应性。重复测试和preorb™处理得到相同的结果。为了调查原因,用酸处理过的珠测试排除了变性HLA抗体。另一种SAB平台(LIFECODES®LSA™)和LABScreen™混合珠均为阴性。与两个无亲缘关系的供体的代用血交叉配型为阴性,证实缺乏细胞反应性抗体。这是第一个记录在案的泛hla - a反应性假阳性的病例,仅限于单一的商业SAB产品。识别这些伪影对于防止抗体特异性的错误分类至关重要。
{"title":"Unique case of False-Positive pan-HLA-A antibody detection in LABScreen single antigen bead assay","authors":"Merschman Jarret,&nbsp;Barnes Rachel,&nbsp;Burmeister Lydia,&nbsp;Kreuter Justin,&nbsp;Park Robyn,&nbsp;Theel Nathan,&nbsp;Wakefield Laurie,&nbsp;Manish J. Gandhi","doi":"10.1016/j.humimm.2026.111682","DOIUrl":"10.1016/j.humimm.2026.111682","url":null,"abstract":"<div><div>Accurate detection of HLA antibodies is essential for assessing immunologic risk in transplantation. Solid-phase antibody assays (SPA), particularly Luminex-based single-antigen bead (SAB) assay offer high sensitivity, but are prone to false reactions that may lead to clinical misinterpretation. While false-positive pan-locus patterns have been described for HLA-C/DR, pan-HLA-A reactivity has not been previously reported.</div><div>We present a patient who developed pan-HLA-A reactivity detected by LABScreen™ SAB one year after combined liver-kidney transplantation. Repeat testing and Presorb™ treatment yielded identical results. To investigate causes, testing with acid-treated beads ruled out antibodies to denatured HLA. An alternative SAB platform (LIFECODES® LSA™) and LABScreen™ Mixed beads were negative. Surrogate flow crossmatches with two unrelated donors were negative, confirming absence of cell-reactive antibodies.</div><div>This represents the first documented case of false-positive pan–HLA-A reactivity confined to a single commercial SAB product. Recognition of such artifacts is essential to prevent misclassification of antibody specificity.</div></div>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 4","pages":"Article 111682"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell transcriptomics reveals targeted modulation of inflammatory repertoire by SOCE blockers 单细胞转录组学揭示了SOCE阻滞剂对炎症库的靶向调节
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-04-01 Epub Date: 2026-02-13 DOI: 10.1016/j.humimm.2026.111687
Andreas Stephanou , Madhav Mantri , Divya Shankaranarayanan , Carol Li , Mila Lagman , Jenny Xiang , Chendong Pan , Yanjie Sun , Thangamani Muthukumar , Khaled Machaca , Iwijn De Vlaminck , Manikkam Suthanthiran
Store-operated calcium entry (SOCE) plays a critical role in regulating intracellular calcium signaling and is essential for immune cell functions. SOCE blockade with the pyrazole derivative BTP2 has been explored as an anti-inflammatory strategy in preclinical models, and Zegocractin (CM4620) is under clinical investigation as a CRAC channel inhibitor with activity in multiple tissues, including immune cells. However, the cell type–specific consequences of SOCE blockade under defined activation contexts remain incompletely understood. Here, we used multiplexed single-cell RNA sequencing to investigate the effects of two prototypic SOCE blockers, BTP2 and CM4620, on polyclonally stimulated, normal human peripheral blood mononuclear cells (PBMCs) in a phytohemagglutinin (PHA)-driven T-cell activation model. The data revealed that SOCE blockade suppressed cytotoxicity-associated transcriptional programs in CD8+ effector T cells and natural killer (NK) cells, restoring them to levels comparable to unstimulated cells. At the same time, SOCE blockade allowed CD4+ regulatory T cells to retain transcriptional signatures associated with immune regulation. These results indicate that, in this experimental model, SOCE blockade dampens cytotoxic programs while maintaining tolerance signatures, suggesting a potential avenue for targeted immune modulation in transplantation and other immune-mediated conditions.

Significance Statement

Store-operated calcium entry (SOCE) is essential for immune activation, but broad immunosuppression can cause significant side effects. Using single-cell transcriptomics in a phytohemagglutinin (PHA)–driven T-cell activation model, we show that SOCE blockade with BTP2 or CM4620 suppresses pro-inflammatory and cytotoxic programs in CD8+ effector T cells and NK cells while preserving tolerance-associated pathways in CD4+ regulatory T cells. These findings suggest that SOCE blockade may provide a more targeted form of immune modulation, warranting future head-to-head comparisons with conventional immunosuppressants. Our results highlight the potential of SOCE blockers to reduce immune-mediated damage while maintaining tolerance, motivating further functional and translational studies in transplantation and other immune-mediated conditions.
储存操作钙进入(SOCE)在调节细胞内钙信号传导中起关键作用,对免疫细胞功能至关重要。吡唑衍生物BTP2阻断SOCE已在临床前模型中作为一种抗炎策略进行了探索,Zegocractin (CM4620)作为一种CRAC通道抑制剂正在临床研究中,在多种组织(包括免疫细胞)中具有活性。然而,在定义的激活环境下,SOCE阻断的细胞类型特异性后果仍然不完全清楚。在这里,我们使用多重单细胞RNA测序来研究两种原型SOCE阻滞剂BTP2和CM4620在植物血凝素(PHA)驱动的t细胞活化模型中对多克隆刺激的正常人外周血单核细胞(PBMCs)的影响。数据显示,SOCE阻断抑制CD8+效应T细胞和自然杀伤(NK)细胞中与细胞毒性相关的转录程序,使它们恢复到与未刺激细胞相当的水平。同时,SOCE阻断允许CD4+调节性T细胞保留与免疫调节相关的转录特征。这些结果表明,在这个实验模型中,SOCE阻断抑制了细胞毒性程序,同时保持了耐受性特征,这表明在移植和其他免疫介导的疾病中靶向免疫调节的潜在途径。存储操作的钙进入(SOCE)是免疫激活所必需的,但广泛的免疫抑制可能导致显著的副作用。在植物血凝素(PHA)驱动的T细胞激活模型中使用单细胞转录组学,我们发现BTP2或CM4620阻断SOCE可以抑制CD8+效应T细胞和NK细胞中的促炎和细胞毒性程序,同时保留CD4+调节性T细胞中的耐受性相关途径。这些发现表明,SOCE阻断可能提供一种更有针对性的免疫调节形式,保证未来与传统免疫抑制剂进行正面比较。我们的研究结果强调了SOCE阻滞剂在维持耐受性的同时减少免疫介导的损伤的潜力,推动了移植和其他免疫介导疾病的进一步功能和转化研究。
{"title":"Single-cell transcriptomics reveals targeted modulation of inflammatory repertoire by SOCE blockers","authors":"Andreas Stephanou ,&nbsp;Madhav Mantri ,&nbsp;Divya Shankaranarayanan ,&nbsp;Carol Li ,&nbsp;Mila Lagman ,&nbsp;Jenny Xiang ,&nbsp;Chendong Pan ,&nbsp;Yanjie Sun ,&nbsp;Thangamani Muthukumar ,&nbsp;Khaled Machaca ,&nbsp;Iwijn De Vlaminck ,&nbsp;Manikkam Suthanthiran","doi":"10.1016/j.humimm.2026.111687","DOIUrl":"10.1016/j.humimm.2026.111687","url":null,"abstract":"<div><div>Store-operated calcium entry (SOCE) plays a critical role in regulating intracellular calcium signaling and is essential for immune cell functions. SOCE blockade with the pyrazole derivative BTP2 has been explored as an anti-inflammatory strategy in preclinical models, and Zegocractin (CM4620) is under clinical investigation as a CRAC channel inhibitor with activity in multiple tissues, including immune cells. However, the cell type–specific consequences of SOCE blockade under defined activation contexts remain incompletely understood. Here, we used multiplexed single-cell RNA sequencing to investigate the effects of two prototypic SOCE blockers, BTP2 and CM4620, on polyclonally stimulated, normal human peripheral blood mononuclear cells (PBMCs) in a phytohemagglutinin (PHA)-driven T-cell activation model. The data revealed that SOCE blockade suppressed cytotoxicity-associated transcriptional programs in CD8<sup>+</sup> effector T cells and natural killer (NK) cells, restoring them to levels comparable to unstimulated cells. At the same time, SOCE blockade allowed CD4<sup>+</sup> regulatory T cells to retain transcriptional signatures associated with immune regulation. These results indicate that, in this experimental model, SOCE blockade dampens cytotoxic programs while maintaining tolerance signatures, suggesting a potential avenue for targeted immune modulation in transplantation and other immune-mediated conditions.</div></div><div><h3><strong>Significance Statement</strong></h3><div>Store-operated calcium entry (SOCE) is essential for immune activation, but broad immunosuppression can cause significant side effects. Using single-cell transcriptomics in a phytohemagglutinin (PHA)–driven T-cell activation model, we show that SOCE blockade with BTP2 or CM4620 suppresses pro-inflammatory and cytotoxic programs in CD8<sup>+</sup> effector T cells and NK cells while preserving tolerance-associated pathways in CD4<sup>+</sup> regulatory T cells. These findings suggest that SOCE blockade may provide a more targeted form of immune modulation, warranting future head-to-head comparisons with conventional immunosuppressants. Our results highlight the potential of SOCE blockers to reduce immune-mediated damage while maintaining tolerance, motivating further functional and translational studies in transplantation and other immune-mediated conditions.</div></div>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 4","pages":"Article 111687"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146192437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between ADAM33 gene polymorphisms and asthma in the Zhuang population of China. 中国壮族人群ADAM33基因多态性与哮喘的关系
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-03-21 DOI: 10.1016/j.humimm.2026.111722
Zan-Mei Qin, Xue-Mei Huang, Xuan Wei, Zhi-Yi He, Jing-Min Deng

Objective: To explore the potential association between five single nucleotide polymorphisms (SNPs) (rs44707, rs612709, rs598418, rs2280089, and rs574174) in the ADAM33 gene and asthma susceptibility in the Zhuang population of Guangxi, China.

Methods: A single-center case-control study was conducted involving 155 asthma patients and 106 healthy controls. Genotyping of the five ADAM33 SNPs were performed using multiplex PCR capture and next-generation sequencing. Association analyses of genotype, allele, and haplotype distributions were conducted, with adjustments for potential confounding factors (age, sex, height, and weight) and Bonferroni correction for multiple testing. Hardy-Weinberg equilibrium (HWE) was verified in the control group to assess population representativeness.

Results: The genotype distributions of all five SNPs in the control group were consistent with HWE (P > 0.05). Before covariate adjustment, significant differences were observed between the case and control groups in the genotype and allele frequencies of rs44707 (genotype: χ2 = 7.180, P = 0.028; allele: χ2 = 5.344, P = 0.021), rs612709 (genotype: χ2 = 6.548, P = 0.029; allele: χ2 = 7.060, P = 0.008), and rs598418 (genotype: χ2 = 8.750, P = 0.013; allele: χ2 = 7.607, P = 0.006). No significant differences were found in the genotype or allele frequencies of rs2280089 and rs574174 between the two groups (P > 0.05). After adjusting for covariates, multiple genetic models (allele, homozygous, recessive) of rs44707, rs612709, and rs598418 still showed significant associations with asthma (P < 0.05). After Bonferroni correction, allele frequency differences retained significance for rs612709 (Padj = 0.040) and rs598418 (Padj = 0.030), but not for rs44707 (genotype Padj = 0.140; allele Padj = 0.105). Haplotype analysis revealed that the frequency of the GGGGC haplotype was significantly higher in the case group than in the control group (χ2 = 6.177, OR = 1.603, 95 % CI: 1.104-2.329, P = 0.013), but this significance was not retained after Bonferroni correction (Padj = 0.065).

Conclusion: This study provides preliminary evidence that rs44707, rs612709, and rs598418 in the ADAM33 gene may be associated with asthma susceptibility in the Zhuang population of Guangxi. The GGGGC haplotype shows a trend of potential association with increased asthma risk, but this finding requires further verification. Given limitations of single-center design, small sample size, these observations require cautious interpretation. Larger multi-center studies with stratified cohorts and functional validation are needed to confirm the role of ADAM33 genetic variants in asthma among this ethnic group.

目的:探讨广西壮族人群ADAM33基因5个单核苷酸多态性(rs44707、rs612709、rss598418、rs2280089和rss574174)与哮喘易感性之间的潜在关联。方法:采用单中心病例对照研究,纳入155例哮喘患者和106例健康对照者。采用多重PCR捕获和新一代测序对5个ADAM33 snp进行基因分型。对基因型、等位基因和单倍型分布进行关联分析,对潜在的混杂因素(年龄、性别、身高和体重)进行调整,并对多重检验进行Bonferroni校正。在对照组中验证Hardy-Weinberg均衡(HWE)以评估群体代表性。结果:对照组5个snp的基因型分布与HWE一致(P < 0.05)。协变量调整前,病例组与对照组rs44707(基因型:χ2 = 7.180, P = 0.028;等位基因:χ2 = 5.344, P = 0.021)、rs612709(基因型:χ2 = 6.548, P = 0.029;等位基因:χ2 = 7.060, P = 0.008)、rss598418(基因型:χ2 = 8.750, P = 0.013;等位基因:χ2 = 7.607, P = 0.006)的基因型和等位基因频率差异均有统计学意义。rs2280089和rss574174基因型和等位基因频率在两组间差异均无统计学意义(P < 0.05)。校正协变量后,rs44707、rs612709和rss598418的多个遗传模型(等位基因、纯合基因、隐性基因)与哮喘的相关性仍显著(P < 0.05)。经Bonferroni校正后,rs612709 (Padj = 0.040)和rss598418 (Padj = 0.030)的等位基因频率差异仍有显著性,而rs44707(基因型Padj = 0.140,等位基因Padj = 0.105)的等位基因频率差异无显著性。单倍型分析显示,病例组GGGGC单倍型出现频率显著高于对照组(χ2 = 6.177, OR = 1.603, 95% CI: 1.104 ~ 2.329, P = 0.013),但经Bonferroni校正(Padj = 0.065)后,差异无统计学意义。结论:本研究为广西壮族人群ADAM33基因rs44707、rs612709和rss598418可能与哮喘易感性相关提供了初步证据。GGGGC单倍型显示出与哮喘风险增加的潜在关联趋势,但这一发现需要进一步验证。考虑到单中心设计的局限性,小样本量,这些观察结果需要谨慎解释。需要更大规模的多中心分层队列研究和功能验证来确认ADAM33遗传变异在该民族哮喘中的作用。
{"title":"Association between ADAM33 gene polymorphisms and asthma in the Zhuang population of China.","authors":"Zan-Mei Qin, Xue-Mei Huang, Xuan Wei, Zhi-Yi He, Jing-Min Deng","doi":"10.1016/j.humimm.2026.111722","DOIUrl":"https://doi.org/10.1016/j.humimm.2026.111722","url":null,"abstract":"<p><strong>Objective: </strong>To explore the potential association between five single nucleotide polymorphisms (SNPs) (rs44707, rs612709, rs598418, rs2280089, and rs574174) in the ADAM33 gene and asthma susceptibility in the Zhuang population of Guangxi, China.</p><p><strong>Methods: </strong>A single-center case-control study was conducted involving 155 asthma patients and 106 healthy controls. Genotyping of the five ADAM33 SNPs were performed using multiplex PCR capture and next-generation sequencing. Association analyses of genotype, allele, and haplotype distributions were conducted, with adjustments for potential confounding factors (age, sex, height, and weight) and Bonferroni correction for multiple testing. Hardy-Weinberg equilibrium (HWE) was verified in the control group to assess population representativeness.</p><p><strong>Results: </strong>The genotype distributions of all five SNPs in the control group were consistent with HWE (P > 0.05). Before covariate adjustment, significant differences were observed between the case and control groups in the genotype and allele frequencies of rs44707 (genotype: χ<sup>2</sup> = 7.180, P = 0.028; allele: χ<sup>2</sup> = 5.344, P = 0.021), rs612709 (genotype: χ<sup>2</sup> = 6.548, P = 0.029; allele: χ<sup>2</sup> = 7.060, P = 0.008), and rs598418 (genotype: χ<sup>2</sup> = 8.750, P = 0.013; allele: χ<sup>2</sup> = 7.607, P = 0.006). No significant differences were found in the genotype or allele frequencies of rs2280089 and rs574174 between the two groups (P > 0.05). After adjusting for covariates, multiple genetic models (allele, homozygous, recessive) of rs44707, rs612709, and rs598418 still showed significant associations with asthma (P < 0.05). After Bonferroni correction, allele frequency differences retained significance for rs612709 (P<sub>adj</sub> = 0.040) and rs598418 (P<sub>adj</sub> = 0.030), but not for rs44707 (genotype P<sub>adj</sub> = 0.140; allele P<sub>adj</sub> = 0.105). Haplotype analysis revealed that the frequency of the GGGGC haplotype was significantly higher in the case group than in the control group (χ<sup>2</sup> = 6.177, OR = 1.603, 95 % CI: 1.104-2.329, P = 0.013), but this significance was not retained after Bonferroni correction (P<sub>adj</sub> = 0.065).</p><p><strong>Conclusion: </strong>This study provides preliminary evidence that rs44707, rs612709, and rs598418 in the ADAM33 gene may be associated with asthma susceptibility in the Zhuang population of Guangxi. The GGGGC haplotype shows a trend of potential association with increased asthma risk, but this finding requires further verification. Given limitations of single-center design, small sample size, these observations require cautious interpretation. Larger multi-center studies with stratified cohorts and functional validation are needed to confirm the role of ADAM33 genetic variants in asthma among this ethnic group.</p>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 5","pages":"111722"},"PeriodicalIF":2.2,"publicationDate":"2026-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-silico design of a therapeutic multi-epitope peptide candidate vaccine against rheumatoid arthritis 一种治疗性多表位候选类风湿关节炎疫苗的芯片设计
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-03-01 Epub Date: 2026-01-12 DOI: 10.1016/j.humimm.2025.111654
Azadeh Mohammadi Sepahvand , Nasrin Azarbani , Fateme Zare , Manica Negahdaripour , Ali Dehshahri
Rheumatoid arthritis (RA) is a systemic autoimmune disease primarily affecting the joints, resulting in inflammation, swelling, and pain, ultimately impacting patients’ quality of life and causing premature death. TNF-α, regulated by the NF-κB transcription factor, is a key cytokine implicated in tissue destruction and disease progression. Both TNF-α and the NF-κB receptor ligand (RANKL) are considered significant targets in the treatment of RA. Due to the limitations of current therapeutic strategies in providing safe and effective long-term healing, there is a clear need for novel therapeutic interventions, including vaccine development. This study aims to design an innovative multi-epitope polypeptide vaccine targeting RA through computational methods. To achieve this goal, epitope sequences from TNF-α and RANKL were predicted using three servers. Adjuvants CTxB, PADRE, and B29 were then incorporated with appropriate linkers. The structure underwent several analyses to assess physicochemical properties, immunogenicity, and allergenicity using various servers. The designed protein showed slightly hydrophilic characteristics with a negative Gravy index and a pI of 8.20. Additionally, with an instability index below 40, the protein demonstrates stability, which is crucial for the vaccine’s effectiveness. To predict the 3D structure, I-TASSER and trRosetta servers were utilized, and the best models underwent refinement using the GalaxyRefine server. Validation of the refined models was performed by the ProSA-web and Ramachandran plot analysis, and the best model was determined. Ultimately, the results of the conformational B-cell epitope prediction of the final model suggested that the designed vaccine can effectively trigger the humoral immune response. The combination of ten epitopes from TNF-α and RANKL linked with CTxB, PADRE, and B29 adjuvants presented a promising therapeutic candidate vaccine for RA.
类风湿性关节炎(RA)是一种主要影响关节的系统性自身免疫性疾病,可导致炎症、肿胀和疼痛,最终影响患者的生活质量并导致过早死亡。TNF-α受NF-κB转录因子调控,是参与组织破坏和疾病进展的关键细胞因子。TNF-α和NF-κB受体配体(RANKL)被认为是治疗RA的重要靶点。由于目前的治疗策略在提供安全和有效的长期愈合方面存在局限性,因此显然需要新的治疗干预措施,包括开发疫苗。本研究旨在通过计算方法设计一种针对RA的创新型多表位多肽疫苗。为了实现这一目标,使用三个服务器预测TNF-α和RANKL的表位序列。然后将佐剂CTxB、PADRE和B29与适当的连接物结合。使用不同的服务器对该结构进行了多次分析,以评估其理化性质、免疫原性和过敏原性。设计的蛋白具有轻微的亲水性,肉汁指数为负,pI为8.20。此外,不稳定指数低于40,表明蛋白质具有稳定性,这对疫苗的有效性至关重要。为了预测三维结构,使用了I-TASSER和trRosetta服务器,并使用GalaxyRefine服务器对最佳模型进行了改进。通过ProSA-web和Ramachandran图分析对改进后的模型进行验证,确定最佳模型。最终模型的构象b细胞表位预测结果表明,所设计的疫苗能够有效触发体液免疫应答。TNF-α和RANKL的10个表位与CTxB、PADRE和B29佐剂结合,是一种有希望的RA治疗候选疫苗。
{"title":"In-silico design of a therapeutic multi-epitope peptide candidate vaccine against rheumatoid arthritis","authors":"Azadeh Mohammadi Sepahvand ,&nbsp;Nasrin Azarbani ,&nbsp;Fateme Zare ,&nbsp;Manica Negahdaripour ,&nbsp;Ali Dehshahri","doi":"10.1016/j.humimm.2025.111654","DOIUrl":"10.1016/j.humimm.2025.111654","url":null,"abstract":"<div><div>Rheumatoid arthritis (RA) is a systemic autoimmune disease primarily affecting the joints, resulting in inflammation, swelling, and pain, ultimately impacting patients’ quality of life and causing premature death. TNF-α, regulated by the NF-κB transcription factor, is a key cytokine implicated in tissue destruction and disease progression. Both TNF-α and the NF-κB receptor ligand (RANKL) are considered significant targets in the treatment of RA. Due to the limitations of current therapeutic strategies in providing safe and effective long-term healing, there is a clear need for novel therapeutic interventions, including vaccine development. This study aims to design an innovative multi-epitope polypeptide vaccine targeting RA through computational methods. To achieve this goal, epitope sequences from TNF-α and RANKL were predicted using three servers. Adjuvants CTxB, PADRE, and B29 were then incorporated with appropriate linkers. The structure underwent several analyses to assess physicochemical properties, immunogenicity, and allergenicity using various servers. The designed protein showed slightly hydrophilic characteristics with a negative Gravy index and a pI of 8.20. Additionally, with an instability index below 40, the protein demonstrates stability, which is crucial for the vaccine’s effectiveness. To predict the 3D structure, I-TASSER and trRosetta servers were utilized, and the best models underwent refinement using the GalaxyRefine server. Validation of the refined models was performed by the ProSA-web and Ramachandran plot analysis, and the best model was determined. Ultimately, the results of the conformational B-cell epitope prediction of the final model suggested that the designed vaccine can effectively trigger the humoral immune response. The combination of ten epitopes from TNF-α and RANKL linked with CTxB, PADRE, and B29 adjuvants presented a promising therapeutic candidate vaccine for RA.</div></div>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 3","pages":"Article 111654"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145947946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multipronged Tα1 reset of CD8+ T cell cytotoxicity against breast cancer CD8+ T细胞对乳腺癌细胞毒性的多管齐下的Tα1复位
IF 2.2 4区 医学 Q3 IMMUNOLOGY Pub Date : 2026-03-01 Epub Date: 2026-01-30 DOI: 10.1016/j.humimm.2026.111678
Smriti Mishra , Gaurang Telang , Anurag Sureshbabu , Samruddhi Kulkarni , Senthil Thayagrajan , A.W Santhosh Kumar , Rajshri Singh
Thymosin α1 (Tα1) is an endogenous thymic peptide that enhances immune competence through activation of T cells, dendritic cells, and innate immune pathways. However, its direct impact on CD8+ T cell–mediated antitumor immunity in breast cancer remains unclear. In this study, CD8+ T cells isolated from peripheral blood of ten healthy donors were cultured under unstimulated, CD3/CD28-stimulated, Tα1-treated, or exhaustion–rescue conditions to evaluate cytotoxic activity against MDA-MB-231 breast cancer cells and CD44+ cancer stem-like cells (CD44+ CSC-like cells). Tα1 significantly enhanced CD8+ T cell–mediated apoptosis, suppressed tumor cell proliferation, and increased granzyme B secretion beyond CD3/CD28 stimulation alone. In exhausted T cells, Tα1 partially restored effector function and reduced PD-1, TIM-3, and LAG-3 expression. Complementary transcriptomic analysis using a compact four-gene Tα1 Response Index (Tα1-RI: TLR9, TLR2, IRF1, NLRC5) in TCGA-BRCA (n = 1,112) confirmed positive correlations with antigen presentation and cytotoxic programs and enrichment in CD8-like T cells in single-cell datasets. Collectively, these findings demonstrate that Tα1 enhances CD8+ T cell cytotoxicity while alleviating exhaustion, supporting its potential as an adjunct immunomodulator for improving immune surveillance in breast cancer.
胸腺肽α1 (Tα1)是一种内源性胸腺肽,通过激活T细胞、树突状细胞和先天免疫途径增强免疫能力。然而,其对CD8+ T细胞介导的乳腺癌抗肿瘤免疫的直接影响尚不清楚。在这项研究中,从10名健康供者的外周血中分离出CD8+ T细胞,分别在未刺激、CD3/ cd28刺激、Tα1处理或衰竭拯救条件下进行培养,以评估对MDA-MB-231乳腺癌细胞和CD44+癌症干细胞样细胞(CD44+ csc样细胞)的细胞毒活性。Tα1比单独刺激CD3/CD28显著增强CD8+ T细胞介导的凋亡,抑制肿瘤细胞增殖,增加颗粒酶B分泌。在衰竭的T细胞中,Tα1部分恢复效应细胞功能,降低PD-1、TIM-3和LAG-3的表达。利用紧凑的四基因Tα1应答指数(Tα1- ri: TLR9, TLR2, IRF1, NLRC5)在TCGA-BRCA (n = 1112)中进行互补转录组学分析,证实了在单细胞数据集中,抗原呈递、细胞毒性程序和cd8样T细胞的富集与Tα1应答指数呈正相关。总之,这些发现表明Tα1增强CD8+ T细胞的细胞毒性,同时减轻衰竭,支持其作为辅助免疫调节剂改善乳腺癌免疫监测的潜力。
{"title":"A multipronged Tα1 reset of CD8+ T cell cytotoxicity against breast cancer","authors":"Smriti Mishra ,&nbsp;Gaurang Telang ,&nbsp;Anurag Sureshbabu ,&nbsp;Samruddhi Kulkarni ,&nbsp;Senthil Thayagrajan ,&nbsp;A.W Santhosh Kumar ,&nbsp;Rajshri Singh","doi":"10.1016/j.humimm.2026.111678","DOIUrl":"10.1016/j.humimm.2026.111678","url":null,"abstract":"<div><div>Thymosin α1 (Tα1) is an endogenous thymic peptide that enhances immune competence through activation of T cells, dendritic cells, and innate immune pathways. However, its direct impact on CD8<sup>+</sup> T cell–mediated antitumor immunity in breast cancer remains unclear. In this study, CD8<sup>+</sup> T cells isolated from peripheral blood of ten healthy donors were cultured under unstimulated, CD3/CD28-stimulated, Tα1-treated, or exhaustion–rescue conditions to evaluate cytotoxic activity against MDA-MB-231 breast cancer cells and CD44<sup>+</sup> cancer stem-like cells (CD44<sup>+</sup> CSC-like cells). Tα1 significantly enhanced CD8<sup>+</sup> T cell–mediated apoptosis, suppressed tumor cell proliferation, and increased granzyme B secretion beyond CD3/CD28 stimulation alone. In exhausted T cells, Tα1 partially restored effector function and reduced PD-1, TIM-3, and LAG-3 expression. Complementary transcriptomic analysis using a compact four-gene Tα1 Response Index (Tα1-RI: TLR9, TLR2, IRF1, NLRC5) in TCGA-BRCA (n = 1,112) confirmed positive correlations with antigen presentation and cytotoxic programs and enrichment in CD8-like T cells in single-cell datasets. Collectively, these findings demonstrate that Tα1 enhances CD8<sup>+</sup> T cell cytotoxicity while alleviating exhaustion, supporting its potential as an adjunct immunomodulator for improving immune surveillance in breast cancer.</div></div>","PeriodicalId":55047,"journal":{"name":"Human Immunology","volume":"87 3","pages":"Article 111678"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1